Cost-effectiveness analysis of recombinant human follicle-stimulating hormone alfa(r-hFSH) and urinary highly purified menopausal gonadotropin (hMG) based on data from a large German registry

This was a retrospective real-world evidence analysis of the costs per live birth for reference recombinant human follicle-stimulating hormone alfa (r-hFSH-alfa) versus highly purified urinary human menopausal gonadotropin (hMG-HP), based on data from a German in vitro fertilization registry (RecDat...

Full description

Saved in:
Bibliographic Details
Published in:Best practice & research. Clinical obstetrics & gynaecology 2022-12, Vol.85 (Pt B), p.188-202
Main Authors: Bühler, Klaus, Roeder, Claudia, Schwarze, Juan-Enrique, Lispi, Monica, Allignol, Arthur, Falla, Edel, Lukyanov, Vasily, D´Hooghe, Thomas, Fischer, Robert
Format: Article
Language:English
Subjects:
Cost-Effectiveness Analysis
Female
Fertilization in Vitro - methods
Follicle Stimulating Hormone - therapeutic use
Follicle Stimulating Hormone, Human - therapeutic use
Gonadotropins
hMG-HP
Humans
IVF
Menotropins - therapeutic use
Ovulation Induction - methods
Pregnancy
r-hFSH-alfa
Retrospective Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This was a retrospective real-world evidence analysis of the costs per live birth for reference recombinant human follicle-stimulating hormone alfa (r-hFSH-alfa) versus highly purified urinary human menopausal gonadotropin (hMG-HP), based on data from a German in vitro fertilization registry (RecDate). Pregnancy and live birth rates from the RecDate real-world evidence study over three complete assisted reproductive technology (ART) cycles using the same gonadotropin drug were used as clinical inputs. Costs related to ART treatment and to drugs were obtained from public sources. Treatment with r-hFSH-alfa resulted in higher adjusted cumulative live birth rates versus hMG-HP after one (25.3% vs. 22.3%), two (30.9% vs. 27.5%), and three (31.9% vs. 28.6%) ART cycles. Costs per live birth were lower with r-hFSH-alfa versus hMG-HP after one (€17,938 vs. €20,054), two (€18,251 vs. €20,437), and three (€18,473 vs. €20,680) ART cycles. r-hFSH-alfa was found to be a cost-effective strategy compared with hMG-HP over three cycles. •Cumulative live birth rates were higher with reference r-hFSH-alfa versus hMG-HP.•Costs per live birth were lower with reference r-hFSH-alfa versus hMG-HP.•Reference r-hFSH-alfa was found to be a cost-effective strategy versus hMG-HP.
ISSN:1521-6934
1532-1932
DOI:10.1016/j.bpobgyn.2022.02.002